SAEN

Genenta Science S.p.A.

There isn't enough reported data to score SAEN yet.

SAEN Fundamentals

MetricStatus
Unavailable
Under pressure
Unavailable
Unavailable

SAEN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.

SAEN PE Valuation

SAEN has no meaningful PE right now: it lost money over the past year.

SAEN Forward outlook

There aren't enough analyst estimates for SAEN to show an outlook.

SAEN Risk to reward

ScenarioChangePrice
UpsideUnknown—
DownsideUnknown—

Calculated from the latest close: $0.62 on Nov 12.

There is not enough scenario data to assess SAEN's risk to reward.

SAEN Earnings Per Share

Q4 2021: $-0.41Q4 2022: $-0.52Q2 2023: $-0.80Q4 2023: $-0.71Q2 2024: $-0.54Q4 2024: $-0.54Q2 2025: $-0.52Q4 2025: $-0.37
Q4 2021: $-0.41Q4 2022: $-0.52Q2 2023: $-0.80Q4 2023: $-0.71Q2 2024: $-0.54Q4 2024: $-0.54Q2 2025: $-0.52Q4 2025: $-0.37
QuarterTTM EPSYoY
Q4 2025-$0.37+$0.17
Q2 2025-$0.52+$0.02
Q4 2024-$0.54+$0.17
Q2 2024-$0.54+$0.26
Q4 2023-$0.71-$0.19
Q4 2022-$0.52-$0.11

SAEN is still losing money, but far less than before: $0.37 per share over the past year, against $0.80 at its worst in mid-2023.

SAEN Quarterly Revenue

Q4 2019: $0Q2 2020: $0Q4 2020: $0Q4 2021: --Q2 2022: --Q4 2022: --Q2 2023: --Q4 2023: --Q2 2024: --Q4 2024: --Q2 2025: --Q4 2025: --
Q4 2019: $0Q2 2020: $0Q4 2020: $0Q4 2021: --Q2 2022: --Q4 2022: --Q2 2023: --Q4 2023: --Q2 2024: --Q4 2024: --Q2 2025: --Q4 2025: --

SAEN Free Cash Flow

Q4 2019: −$1MQ2 2020: −$2MQ4 2020: −$5MQ4 2021: −$8MQ2 2022: −$3MQ4 2022: −$5MQ2 2023: −$8MQ4 2023: −$4MQ2 2024: −$2MQ4 2024: −$5MQ2 2025: −$6MQ4 2025: −$2M
Q4 2019: −$1MQ2 2020: −$2MQ4 2020: −$5MQ4 2021: −$8MQ2 2022: −$3MQ4 2022: −$5MQ2 2023: −$8MQ4 2023: −$4MQ2 2024: −$2MQ4 2024: −$5MQ2 2025: −$6MQ4 2025: −$2M
QuarterFree cash flowYoY
Q4 2025-$1.5M+$3.1M
Q2 2025-$6.1M-$3.8M
Q4 2024-$4.6M-$620.3K
Q2 2024-$2.3M+$6.1M
Q4 2023-$4M+$1.4M
Q2 2023-$8.4M-$5.6M
Q4 2022-$5.4M+$2.3M
Q4 2021-$7.7M-$3.2M

SAEN has burned cash in almost every quarter: −$15M over the past year, against −$21M the year before.

SAEN Total Shares

Q4 2019: 18MQ2 2020: 14MQ4 2020: 15MQ4 2021: 15MQ2 2022: 18MQ4 2022: 18MQ2 2023: 18MQ4 2023: 18MQ2 2024: 18MQ4 2024: 18MQ2 2025: 19MQ4 2025: 20M
Q4 2019: 18MQ2 2020: 14MQ4 2020: 15MQ4 2021: 15MQ2 2022: 18MQ4 2022: 18MQ2 2023: 18MQ4 2023: 18MQ2 2024: 18MQ4 2024: 18MQ2 2025: 19MQ4 2025: 20M
PeriodChange %Net change
Quarterly+5%+942K shares
1 year+8.2%+1.5M shares
3 years+8.8%+1.6M shares

SAEN has 20M diluted shares, up 8.2% from a year ago.

SAEN Net Leverage

SAEN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.

SAEN Weekly Momentum

MetricValueStatus
RSI36.4Neutral
Stochastic7.6Oversold

SAEN's weekly RSI is 36 (neutral) and its Stochastic is 8 (oversold).

SAEN PE vs Healthcare Sector

SAEN has no meaningful PE right now: it lost money over the past year.

SAEN Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$0.688.8% below
20 week MA$1.0340% below
50 week MA$1.0843% below
100 week MA$2.3974% below
200 week MA$3.6583% below

SAEN is in a downtrend: it's below all five of its weekly moving averages, and 83% below its 200-week average.

SAEN Yearly ROI

YearStart priceEnd priceROI
2021$11.0$11.9+7.5%
2022$11.9$5.51-54%
2023$5.51$4.95-10%
2024$4.95$4.88-1.4%
2025$4.88$1.46-70%
2026 YTD$1.46$0.62-58%

SAEN has finished four years in a row lower, and it's down 58% so far in 2026.

Give your agent the market.

Get API key